Pharma Stock Outperforms S&P 500 Over Ten Years
An unnamed pharmaceutical stock has outperformed the S&P 500 over a ten-year period, according to a new report. Sustained outperformance in drug equities typically reflects durable patent protection, pricing power, and pipeline execution compounding over time.